Rossella Manfredini

Prof. Rossella Manfredini

University of Modena & Reggio Emilia
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2013 in Leukemia
Verified
Journal Article
Closed access
PDF file
AVAlessandro Maria Vannucchi
Alessandro Maria Vannucchi
TLT L Lasho
T L Lasho
PGPaola Guglielmelli
Paola Guglielmelli
FBFlavia Biamonte
Flavia Biamonte
APA Pardanani
A Pardanani
ATA Tefferi
A Tefferi

19 February 2014 in Leukemia
Verified
Journal Article
Closed access
PDF file
PGPaola Guglielmelli
Paola Guglielmelli
TLT L Lasho
T L Lasho
GRG Rotunno
G Rotunno
JSJ Score
J Score
CMC Mannarelli
C Mannarelli
ATA Tefferi
A Tefferi

1 July 2006 in Blood
Verified
Journal Article
Closed access
PDF file
SRSergio Rutella
Sergio Rutella
GBGiuseppina Bonanno
Giuseppina Bonanno
APAnnabella Procoli
Annabella Procoli
AMAndrea Mariotti
Andrea Mariotti
DRDaniela G. de Ritis
Daniela G. de Ritis
RLRoberto M. Lemoli
Roberto M. Lemoli
Several hematopoietic growth factors, including interleukin-10 (IL-10) and transforming growth factor-β1 (TGF-β1), promote the differentiation of tolerogenic dendritic cells (DCs). Hepatocyte growth factor (HGF) is a pleiotropic cytokine whose effects on human DC differentiation and function have not been investigated. Monocytes cultured with HGF (HGFMo) differentiated into accessory cells with DC-like morphology, released low amounts of IL-12p70 and up-regulated IL-10 both at the mRNA and at the protein level. Upon activation with HGFMo, allogeneic CD4+CD25- T cells expressed the T regulatory (Treg)-associated transcription factor FoxP3, proliferated poorly, and released high levels of IL-10. Interestingly, blockade of surface immunoglobulin-like transcript 3 (ILT3) on HGFMo or neutralization of secreted IL-10 translated into partial restoration of T-cell proliferation. Secondary stimulation of HGFMo-primed CD4+ T cells with immunogenic DCs differentiated with granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4 from monocytes of the same donor resulted in measurable T-cell proliferation. HGFMo-primed CD4+ T cells significantly inhibited the proliferation of naive CD4+CD25- T cells in a cell-contact-dependent manner. Finally, DNA microarray analysis revealed a unique gene-expression profile of HGF-activated monocytes. Collectively, our findings point to a novel role for HGF in the regulation of monocyte/DC functions that might be exploited therapeutically. (Blood. 2006;108:218-227)

1 July 1994 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
Carlo PincelliCarlo Pincelli
Carlo Pincelli
CSCinzia Sevignani
Cinzia Sevignani
RMRossella Manfredini
Rossella Manfredini
AGAlexis Grande
Alexis Grande
FFFabrizio Fantini
Fabrizio Fantini
AGAlberto Giannetti
Alberto Giannetti

3 April 2014 in Blood
Verified
Journal Article
Closed access
PDF file
PGPaola Guglielmelli
Paola Guglielmelli
FBFlavia Biamonte
Flavia Biamonte
GRGiada Rotunno
Giada Rotunno
VAValentina Artusi
Valentina Artusi
LALucia Artuso
Lucia Artuso
AVAlessandro M. Vannucchi
Alessandro M. Vannucchi
The JAK1/JAK2 inhibitor ruxolitinib produced significant reductions in splenomegaly and symptomatic burden and improved survival in patients with myelofibrosis (MF), irrespective of their JAK2 mutation status, in 2 phase III studies against placebo (COMFORT-I) and best available therapy (COMFORT-II). We performed a comprehensive mutation analysis to evaluate the impact of 14 MF-associated mutations on clinical outcomes in 166 patients included in COMFORT-II. We found that responses in splenomegaly and symptoms, as well as the risk of developing ruxolitinib-associated anemia and thrombocytopenia, occurred at similar frequencies across different mutation profiles. Ruxolitinib improved survival independent of mutation profile and reduced the risk of death in patients harboring a set of prognostically detrimental mutations (ASXL1, EZH2, SRSF2, IDH1/2) with an hazard ratio of 0.57 (95% confidence interval: 0.30-1.08) vs best available therapy. These data indicate that clinical efficacy and survival improvement may occur across different molecular subsets of patients with MF treated with ruxolitinib. Key Points Improvements in splenomegaly and symptoms in patients receiving ruxolitinib occurred regardless of the mutations that were present. Ruxolitinib relieved the negative impact of prognostically detrimental mutations in myelofibrosis patients from the COMFORT-II study.

25 September 2014 in Blood
Verified
Journal Article
Open access
PDF file
RNRuggiero Norfo
Ruggiero Norfo
RZRoberta Zini
Roberta Zini
VPValentina Pennucci
Valentina Pennucci
EBELISA BIANCHI
ELISA BIANCHI
SSSimona Salati
Simona Salati
RMRossella Manfredini
Rossella Manfredini
Key Points: Differential gene and miRNA expression analysis in PMF granulocytes identifies new biomarkers and putative therapeutic targets. Activation of the miR-155/JARID2 axis in PMF CD34+ cells results in overproduction of MK precursors.